MYC and cancer: p21 is often decreased in human cancer through loss of functional p53 or hyperactive oncogenes like c-Myc: p53 mutations have been discovered in more than 50% of human malignancies [154], whereas c-Myc, p21’s transcriptional repressor [32], is often overexpressed in human cancer [155].